Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Oxolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxolamine SCHEMBL4414451 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Oxolamine SCHEMBL893333 | 0.85 | HTR1A (1.00) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Oxolamine SCHEMBL1652318 | 0.83 | HTR1A (0.97) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Oxolamine SCHEMBL5023142 | 0.82 | CYP1A2 (0.67) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Proxazole SCHEMBL8935625 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Proxazole SCHEMBL41604 | 0.81 | CYP1A2 (0.68) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| Proxazole SCHEMBL21827680 | 0.75 | CYP1A2 (0.59) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| SCHEMBL29376403 | 0.70 | HTR1A (0.71) | CYP1A2CYP2D6HIF1AHTR1AHRH3 | |
| SCHEMBL14288613 | 0.70 | RAB9A (0.70) | CYP1A2HTR1AHRH3MEN1KMT2A | |
| SCHEMBL562989 | 0.69 | ALDH1A1 (1.00) | CYP1A2CYP2D6LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021021055-A1 | COMBINATION OF OXOLAMINE AND TERBUTALINE | EGILMEZ MEHMET VEDAT (TR) | 2021-02-04 | — | — | WO | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| US-12055539-B2 | HDAC1/2 activator for promoting and/or accelerating myelination and/or remyelination | UNIVERSITE DE FRIBOURG (CH) | 2024-08-06 | — | — | US | disclosed |
| CN-115869306-B | Application of IOWH-032 in preparation of medicine for resisting gram-positive bacterial infection | 华中科技大学协和深圳医院 | 2024-03-19 | — | — | CN | disclosed |
| CN-115869306-A | Application of IOWH-032 in preparation of medicines for resisting gram-positive bacterial infection | 华中科技大学协和深圳医院 | 2023-03-31 | — | — | CN | disclosed |
| US-20220334101-A1 | MODULATING EXTRACELLULAR MATRIX MOVEMENT | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-10-20 | — | — | US | disclosed |
| EP-4014038-A1 | MODULATING EXTRACELLULAR MATRIX MOVEMENT | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210340025-A1 | Compositions and Methods for Purification of Metals from Steel Making Waste Streams | CYCAD GROUP, LLC | 2021-11-04 | — | — | US | disclosed |
| WO-2012112933-A1 | DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-08-23 | — | — | WO | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20090325999-A1 | PERSONALIZED PHARMACEUTICAL KITS, PACKAGING AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC CONDITIONS | JDP THERAPEUTICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | MEN1 3082/4885CYP1A2 3883/4885CYP2D6 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.